Skip to main content

The cost of medication can be a significant burden to people with kidney disease.  A 2018 report from The Kidney Foundation of Canada found that 19% of survey respondents had missed purchasing medication in the previous six months due to a financial barrier.  The average reported cost of prescription drugs was $756 per year, and that cost rose to $1,083 when non-prescription medications were taken into account.

The Kidney Foundation of Canada supports the kidney community by participating in Common Drug Reviews, which evaluate drugs based on clinical, economic, and patient evidence and make recommendations as to which medications should be included in federal, provincial and territorial drug plans (except in Quebec, where the review process is managed by INESSS). 

You can participate by completing surveys of your experience with certain medications.  You’ll find the patient input surveys that are currently open on our Participate in a Study page.

You can also review our previous submissions:

Patient Input – veltassa

Patient Input – dapagliflozin

Patient Input – finerenone

Patient Input – maribavir

Patient Input – difelikefalin